<DOC>
	<DOCNO>NCT01594099</DOCNO>
	<brief_summary>The purpose study evaluate efficiency safety weekly Cisplatin /Liposome paclitaxel concurrent chemoradiothrapy treatment locally advanced cervical cancer elderly woman .</brief_summary>
	<brief_title>Concurrent Chemoradiotherapy Cervical Cancer Elderly Women</brief_title>
	<detailed_description>Concurrent radiotherapy standard treatment inoperable cervical cancer .Due physical condition , elderly patient usually associate medical complication , generally receive radiotherapy alone . Recently , retrospective study show impact chemotherapy cause increase complication rate among elderly patient compare young patient cervical cancer , may improve survival concurrent radiotherapy . Cisplatin paclitaxel two effective drug treat cervical cancer , whether safe enough elderly concurrent radiotherapy , clearly report . In study , replace conventional dose chemotherapy weekly cisplatin lipsome paclitaxel , compare efficiency safety weekly cisplatin / liposome paclitaxel concurrent chemoradiotherapy radiotherapy alone treatment cervical cancer elderly patient .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Histologically proven squamous carcinoma cervix 2 . FIGO stageⅡB ⅢB 3 . Over 65 year 4 . Do receive treatment 5 . Performance index ECOG grade 0 2 6 . Normal ECG 7 . Normal hematological parameter 8 . Normal renal liver function test 1 . Concomitant disease may adversely affect outcome 2 . Poor nutritional status 3 . Medical psychological condition preclude treatment 4 . Previous treatment 5 . Concurrent treatment cancer</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>cervical cancer</keyword>
	<keyword>elderly woman</keyword>
	<keyword>concurrent chemotherapy</keyword>
</DOC>